Amgen Inc. (AMGN) FY2025 Q1 P&L / Income Statement

Amgen Inc. (AMGN) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

8,149,000,000 US dollars

Cost of sales

2,968,000,000 US dollars

Gross profit (calculated)

5,181,000,000 US dollars

Operating expenses (calculated)

4,003,000,000 US dollars

Operating income

1,178,000,000 US dollars

Other income (expense), net (calculated)

795,000,000 US dollars

Income (loss) before income taxes

1,973,000,000 US dollars

Provision for income taxes

243,000,000 US dollars

Net income (loss)

1,730,000,000 US dollars

Prolia

1,099,000,000 US dollars

Repatha

656,000,000 US dollars

XGEVA

566,000,000 US dollars

ENBREL

510,000,000 US dollars

EVENITY

442,000,000 US dollars

Otezla

437,000,000 US dollars

TEPEZZA

381,000,000 US dollars

BLINCYTO

370,000,000 US dollars

Aranesp

340,000,000 US dollars

Kyprolis

324,000,000 US dollars

Nplate

313,000,000 US dollars

TEZSPIRE

285,000,000 US dollars

Vectibix

267,000,000 US dollars

KRYSTEXXA

236,000,000 US dollars

Other products

1,647,000,000 US dollars

Other revenues

276,000,000 US dollars

Selling, general and administrative

1,687,000,000 US dollars

Research and development

1,486,000,000 US dollars

Other

830,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.